Soliris to Stop Immune-Mediated Death in COVID-19 (SOLID-C19)-A Compassionate-Use Study of Terminal Complement Blockade in Critically Ill Patients with COVID-19-Related Adult Respiratory Distress Syndrome.
Viruses
; 13(12)2021 12 03.
Article
in English
| MEDLINE | ID: covidwho-1554959
ABSTRACT
Eculizumab, a terminal complement (C5)-inhibiting monoclonal antibody, was administered in five mechanically ventilated patients in life-threatening condition due to COVID-19-related acute respiratory distress syndrome (ARDS) between 23 March 2020 and 3 April 2020. Their clinical progress was monitored. The primary endpoint was mortality. One patient was excluded while two passed away. The remaining two patients survived. At the time of this study, the mortality rate in mechanically ventilated COVID-19 patients suffering from ARDS receiving the standard of care as their therapeutic regimen was reportedly as high as 97%. This pilot study demonstrates a 50% mortality rate in patients receiving eculizumab therapy.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Complement System Proteins
/
Compassionate Use Trials
/
Antibodies, Monoclonal, Humanized
/
COVID-19
Type of study:
Prognostic study
/
Randomized controlled trials
Limits:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
/
Young adult
Language:
English
Year:
2021
Document Type:
Article
Affiliation country:
V13122429
Similar
MEDLINE
...
LILACS
LIS